ELELYSO
(Taliglucerase alfa)ApprovedProtein / enzyme
ELELYSO is one of 4 small molecule programs targeting Gaucher Disease. It is currently in Approved.
1
Indications
5
Total Trials
0
Active Trials
3
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Gaucher Disease
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Approved
Busulfex
Akero TherapeuticsApproved
ELELYSO
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
AZ-3102
AAzafaros A.G.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gaucher Disease3 trials
Regulatory
FDA Approval Timeline[4]
May 1, 2012
ELELYSO
BLA BLA022458
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Taliglucerase alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details